Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13509 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Molecular Oncology, 2023. Verfasst von Shengyu Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Nursing Department, School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Medical and Health Research Projects.
Abstract (Originalsprache)
ROS proto‐oncogene 1, receptor tyrosine kinase ( ROS1 ) rearrangements are a crucial therapeutic target in non‐small cell lung cancer (NSCLC). However, there is limited comprehensive analysis of the molecular patterns of ROS1 fusions. This study aimed to address this gap by analysing 135 ROS1 fusions from 134 Chinese NSCLC patients using next‐generation sequencing (NGS). The fusions were categorized into common and uncommon based on their incidence. Our study revealed, for the first time, a unique distribution preference of breakpoints within ROS1 , with common fusions occurring in introns 31–33 and uncommon fusions occurring in introns 34 and 35. Additionally, we identified previously unknown breakpoints within intron 28 of ROS1 . Furthermore, we identified a close association between the distribution patterns of fusion partners and breakpoints on ROS1 , providing important insights into the molecular landscape of ROS1 fusions. We also confirmed the presence of inconsistent breakpoints in ROS1 fusions between DNA‐based NGS and RNA‐based NGS through rigorous validation methods. These inconsistencies were attributed to alternative splicing resulting in out‐of‐frame or exonic ROS1 fusions. These findings significantly contribute to our understanding of the molecular characteristics of ROS1 fusions, which have implications for panel design and the treatment of NSCLC patients with ROS1 rearrangements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Nursing Department, School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Respiratory and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Jichenjunchuang Clinical Laboratory, Hangzhou, China.
- Genecn-Biotech Co.Ltd, Hangzhou, China.
- Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
ORCID-Profile: Tonghui Ma, Jiao Feng
Förderung
- Zhejiang Province Medical and Health Research Projects
Zitieren
APA
Zhou, S., Zhang, F., Xu, M., Zhang, L., Liu, Z., Yang, Q., Wang, C., Wang, B., Ma, T., & Feng, J. (2023). Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study. Molecular Oncology. https://doi.org/10.1002/1878-0261.13509
Vancouver
Zhou S, Zhang F, Xu M, Zhang L, Liu Z, Yang Q, et al. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study. Molecular Oncology. 2023. doi:10.1002/1878-0261.13509
BibTeX
@article{Zhou2023,
author = {Zhou, Shengyu and Zhang, Fayan and Xu, Mengxiang and Zhang, Lei and Liu, Zhengchuang and Yang, Qiong and Wang, Chunyang and Wang, Baoming and Ma, Tonghui and Feng, Jiao},
title = {Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13509}
}
EUVIMED